What Allegra M Treats: Main Uses and Benefits

The Fexofenadine/Montelukast combination is generally applied across domains where additional symptomatic support is needed, especially relevant in conditions characterized by periods of heightened symptoms. This therapeutic approach is relevant in contexts involving heightened systemic burden. Its primary benefit generally contributes to easing symptoms related to inflammatory or irritative states across the nose, eyes, and skin. It is commonly used across conditions presenting with acute episodes of Seasonal and Perennial Allergic Rhinitis and for the management of Chronic Idiopathic Urticaria.

The combination helps address symptom clusters that interfere with daily comfort, such as symptoms related to inflammatory or irritative states like frequent sneezing, pronounced nasal congestion, runny nose, itchy eyes, and persistent skin itching and swelling.

Applied in scenarios where additional management of discomfort is required, this approach is relevant when functional stability becomes affected.

“The medication supports the patient during difficult episodes and is relevant for easing the impact of persistent allergic airway discomfort.”

Quick Fact: Relief for Functional Strain The formulation helps address the discomfort associated with pronounced nasal congestion, which can be a key source of functional strain for patients.

Regulatory References

1. NIH MedlinePlus overview of Fexofenadine

Eligibility and Contraindications for Allegra M

Official regulatory documents define specific populations who are eligible, restricted, or prohibited from using the Fexofenadine/Montelukast combination product. This information is based on labeled contraindications, age restrictions, and the patient's underlying health status.

---

Eligibility Status Summary

Status	Population Criteria
Contraindicated	Patients with a known hypersensitivity to Fexofenadine, Montelukast, or any excipient. Contraindicated in individuals with rare hereditary metabolic disorders (e.g., Lapp lactase deficiency).
Absolute Exclusion	The medication must never be used to treat acute asthma attacks.
Standard Eligible Age	Adults and adolescents 15 years of age and older. Use in infants and young children (e.g., below 6 months) has not had safety and effectiveness established.
Conditional Use	Pregnancy: Use is permitted only if the potential benefit outweighs the potential risk to the fetus. Lactation: Use is not recommended as components may transfer into breast milk.
Special Caution	Patients with renal impairment, a history of cardiovascular disease, and the elderly should be administered the product with care. Use is not assessed in cases of severe hepatic impairment.

---

These criteria establish that the medicine is reserved for populations where its use has been formally reviewed and deemed acceptable by regulatory authorities under labeled conditions, ensuring adherence to official eligibility requirements.

The official interaction profile for this fixed-dose combination is defined by distinct pharmacokinetic effects on its two active components, with no formal drug-drug contraindications listed due to interaction risk.

Pharmacokinetic and Timing Restrictions

Fexofenadine systemic exposure is susceptible to transporter-mediated interactions. Co-administration with aluminum and magnesium hydroxide-containing antacids requires a separation of at least 2 hours, as antacids physically reduce Fexofenadine absorption. Consuming Grapefruit, Orange, or Apple Juices is restricted, as these beverages inhibit uptake transporters (P-gp/OATP) and reduce the drug's bioavailability. Other P-gp modulators, such as the inhibitor Ketoconazole or the inducer Apalutamide, are documented to significantly alter Fexofenadine plasma levels.

Montelukast systemic exposure is primarily managed by CYP 2C8 metabolic interactions. Co-administration with the strong CYP 2C8 inhibitor Gemfibrozil is documented to cause a 4.4-fold increase in Montelukast’s total exposure.

Population and Compound-Specific Constraints

Official regulatory labels note that patients with renal impairment face a greater risk of toxic reaction due to decreased Fexofenadine clearance. Additionally, there is a label-based restriction that patients with Aspirin sensitivity must continue to avoid NSAIDs while receiving the Montelukast component.

Allegra M functions by engaging two distinct but complementary mechanistic domains to influence the allergic and inflammatory response pathways.

---

1. Peripheral H1-Receptor Antagonism (Fexofenadine)

This component works by targeting the Histamine H1 receptors located on peripheral cells. It acts by initiating a signaling suppression sequence, competing with the mediator histamine to block receptor activation. This dampens excessive signaling within pathways regulated by histamine, contributing to modulation of physiological responses mediated by H1 receptor activation.

---

2. CysLT1-Receptor Modulation (Montelukast)

The second component modulates the leukotriene cascade by acting as a selective antagonist on the CysLT1 receptors. This modifies the secondary molecular steps by limiting the binding of pro-inflammatory leukotrienes (LTC4, LTD4, LTE4). This mechanism operates within the leukotriene signaling cascade, influencing signaling patterns that mediate leukotriene-driven physiological responses.

---

The combined action on these two independent pathways results in dual modulation of the histamine and leukotriene pathways.

Instruction Map: How to use Allegra M — Official Administration Guidelines

The administration of the Fexofenadine 120 mg / Montelukast 10 mg fixed-dose combination must adhere strictly to the usage guidelines established by regulatory authorities.

---

Parameter	Instruction
Route of administration	Oral administration of the film-coated tablet only.
Dosing schedule	The standard recommended dose is one tablet once daily for adults and adolescents 15 years.
Timing in relation to meals	The Fexofenadine component is often advised to be taken before a meal, and all forms should be taken with water. Avoid consuming the tablet with fruit juices (grapefruit, apple, or orange) as this reduces absorption.
Preparation requirements	The tablet must be swallowed whole; it should not be divided, crushed, or chewed.
Age-group administration rules	The prescribed dose is for Adults and Adolescents (15 years). No dosage adjustment is required for geriatric use or for patients with mild to moderate hepatic impairment.
Missed-dose rules	If a dose is missed, regulatory guidance generally advises skipping it and resuming the next scheduled dose; a double dose should not be taken to compensate.
Special procedural conditions	Co-administration with aluminum or magnesium antacids should be avoided or spaced by at least two hours to prevent interference with Fexofenadine absorption.

---

Resulting Procedural Structure

Official Step Sequence:

• The film-coated tablet is administered orally once per day.
• It must be swallowed whole with water.
• The administration should be continuous daily for the prescribed duration of treatment.

Connection to the Overall Use Protocol

This structured approach defines the fixed, once-daily oral administration as the mandatory procedural standard. These instructions clearly limit the maximum daily dose and stipulate specific dietary constraints and timing rules, ensuring the drug is used precisely as documented in the official prescribing information without introducing unauthorized variables.

The research structure for the clinical evaluation of the Fexofenadine and Montelukast combination product includes studies such as Randomized Controlled Trials (RCTs) and scientific systematic reviews. This research examines the combination in comparison with using the individual agents alone across conditions characterized by fluctuating or episodic manifestations.

## Evidence for Use in Allergic Rhinitis

Studies were conducted in populations of adults and adolescents (typically ge 12 years) with conditions where symptoms may vary in intensity. Research examined outcomes linked to inflammatory or irritative states by monitoring changes in standardized total symptom scores (TNSS), as well as specific outcomes related to physical discomfort, such as sneezing, nasal itching, rhinorrhea (runny nose), and nasal congestion.

Studies reported measurements of changes during the study period when exploring the combination compared to the use of Fexofenadine or Montelukast alone. Some trials described patterns where the combination was associated with distinct changes in daytime nasal symptom scores. Furthermore, specific bioequivalence studies reported that the rate and extent of absorption for the fixed-dose tablet were comparable to administering the two medicines separately.

## Evidence for Use in Chronic Urticaria

The combination was studied for its use in patients whose symptoms were observed in some studies to be inadequately addressed by using antihistamine monotherapy alone. Studies monitored changes in objective disease activity indicators, including the size and number of wheals (hives) and the severity of pruritus (itching). Scientific reviews noted that studies exploring the leukotriene component (Montelukast) in chronic urticaria trials reported mixed or inconsistent findings across the scientific literature.

## Evidence Gaps and Areas of Uncertainty

Long-term effects are not fully established; research so far indicates that while the combination was studied over short time intervals, evidence provides limited insight into the durability of observed patterns over many months. Additionally, studies monitoring effects for infants below six months of age have not been established in the existing evidence landscape.

Common questions about Allegra M (FAQ)

Q: Does Allegra M help to reduce inflammation as well as allergy symptoms?

Allegra M is a dual-component product. The leukotriene component (montelukast) is described in official documents as blocking the action of leukotrienes, which are chemical messengers that contribute to swelling. This mechanism describes how the leukotriene component is thought to influence inflammatory pathways.

Q: What is the difference between Allegra M and regular Allegra (fexofenadine)?

Allegra M is a fixed-dose combination medication, meaning it contains two active ingredients in one tablet. It includes the antihistamine Fexofenadine (which is regular Allegra) plus the leukotriene receptor antagonist Montelukast. Regular Allegra only contains Fexofenadine.

Q: Is Allegra M a steroid-based medication?

No, Allegra M is not classified as a steroid. According to official product information, it is categorized as a combination of a second-generation antihistamine (Fexofenadine) and a leukotriene receptor antagonist (Montelukast). This dual classification describes how the medicine works in the body.

Q: Is Allegra M approved for treating symptoms of chronic hives (urticaria)?

The Fexofenadine component of Allegra M is individually approved for treating chronic idiopathic urticaria (hives). The combination approach is typically considered for use when allergic symptoms do not achieve sufficient relief from a single agent.

Q: Is Allegra M commonly used to treat symptoms of skin allergies or rashes?

Official information indicates that the antihistamine component (Fexofenadine) is specifically useful for relieving symptoms of urticaria (hives) and the associated itching of the skin. Its use in the combination is consistent with the purpose of providing sustained anti-allergic action for various symptom types.

Q: Can Allegra M cause side effects such as anxiety or trouble sleeping?

Yes, regulatory labeling notes that the montelukast component has been associated with serious neuropsychiatric events in post-marketing reports. These events, which are classified as rare or very rare, may include psychological changes such as agitation and anxiety, as well as sleep-related issues like insomnia (trouble sleeping).

Q: What are the signs of a rare, serious side effect from Allegra M to be aware of?

Signs of a severe allergic reaction can include sudden onset of hives, rash, difficulty breathing, or swelling of the face, throat, tongue, or lips. Serious mood changes may involve behavioral changes, nightmares, or the onset of suicidal thinking or behavior, as noted in the official safety documents.

Q: Are there any specific vitamins, minerals, or supplements that may interact with Allegra M?

Official labeling specifically notes that co-administration with antacids containing aluminum and magnesium requires a separation of at least two hours to prevent interference with absorption. Regulatory documents note that information about the use of any non-prescription products, including supplements, is a standard component of patient history.

Q: Are there general precautions for using Allegra M if a person has a history of liver conditions?

Official documents state that a dosage adjustment is generally not required for patients who have mild-to-moderate hepatic (liver) impairment. However, use in cases of severe liver impairment has not been formally assessed by regulatory authorities.

Q: Is a generic or store-brand equivalent of Allegra M available for purchase?

The two active ingredients in Allegra M, Fexofenadine and Montelukast, are individually available as generic medications in many markets. Availability of the specific fixed-dose combination product as a generic or store-brand equivalent may vary depending on local regulatory approval.

Storage and Disposal Requirements for Allegra M

Official labeling mandates specific conditions to maintain product stability. The tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C (86 F).

Mandatory Conditions

• Protection: The medicine must be kept in its original, closed container and protected from excessive moisture, heat, and direct light.
• Prohibition: Do not freeze the tablets. The packaging integrity must be maintained; do not use the product if the individual blister units are torn or opened.
• Safety: It is a regulatory requirement to keep this medicine out of the sight and reach of children.

Disposal Instructions

Do not dispose of unused or expired Allegra M by flushing it down the toilet or sink. Patients must consult a healthcare professional or local waste authority for instructions on proper disposal. If discarded in household trash, the tablets must first be mixed with an undesirable substance, such as coffee grounds, and sealed in a bag.